Cargando…
Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
P218 is a highly selective dihydrofolate reductase inhibitor with potent in vitro activity against pyrimethamine-resistant Plasmodium falciparum. This single-center, randomized, double-blind, placebo-controlled phase Ib study evaluated P218 safety, pharmacokinetics, and chemoprotective efficacy in a...
Autores principales: | Chughlay, Mohamed Farouk, El Gaaloul, Myriam, Donini, Cristina, Campo, Brice, Berghmans, Pieter-Jan, Lucardie, Alexander, Marx, Michael W., Cherkaoui-Rbati, Mohammed H., Langdon, Grant, Angulo-Barturen, Iñigo, Viera, Sara, Rosanas-Urgell, Anna, Van Geertruyden, Jean-Pierre, Chalon, Stephan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045640/ https://www.ncbi.nlm.nih.gov/pubmed/33556040 http://dx.doi.org/10.4269/ajtmh.20-1165 |
Ejemplares similares
-
First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection
por: Chughlay, M. Farouk, et al.
Publicado: (2020) -
Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs
por: Chughlay, M. Farouk, et al.
Publicado: (2022) -
Concentration‐QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers
por: Täubel, Jӧrg, et al.
Publicado: (2021) -
A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria
por: Cherkaoui‐Rbati, Mohammed H., et al.
Publicado: (2022) -
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials
por: Antonova-Koch, Yevgeniya, et al.
Publicado: (2018)